OBJECTIVE: To assess validity of pain and patient global scales in gout. METHODS: The authors used data from pegloticase clinical trials in chronic refractory gout to examine the validity of visual analogue scale (VAS) pain, Short-Form 36 (SF-36) bodily pain subscale and VAS patient global assessment (all scales 0-100). Convergent/divergent validity with clinical characteristics was tested by using Spearman's correlation coefficient. For discriminant ability, the authors compared the change at 6 months between placebo and pegloticase arms and calculated effect size (ES) and standardised response mean (SRM). RESULTS:212 patients (mean age, 55.4 years, 82% men; 73% with tophaceous gout) provided data. VAS pain was statistically significantly correlated with tender joints (r=0.42), swollen joints (r=0.30), SF-36 physical (r=-0.56) and Mental Component Summary (r=-0.36) and Health AssessmentQuestionnaire scores (r=0.54; all p-values <0.0001), but not disease duration (r=-0.01; p=0.84), gout flares (r=0.12; p=0.08), comorbidities (r=0.05; p=0.47) or plasma urate (r=0.01; p=0.89). Similar and significant correlation coefficients with tender and swollen joints were noted for VAS patient global assessment (r=0.35 and 0.23; p<0.0012 for both) and SF-36 pain subscale (r=-0.27 and -0.19; p<0.006 for both). Pegloticase group had significantly more improvement than placebo at 6 months, mean (SD): VAS pain, -9.2 (29.3) versus 1.9 (26.4), p=0.0002; SF-36 pain, 14.6 (25.6) versus -0.04 (21.1), p<0.0001; and patient global, -9.3 (26.5) versus 3.4 (22.8), p<0.0001. ES and SRMs in pegloticase group were as follows: VAS pain, 0.34 and 0.30; SF-36 pain, 0.69 and 0.57; patient global, 0.49 and 0.44. CONCLUSION:VAS pain, SF-36 pain and patient global VAS are valid outcome measures in patients with chronic gout.
RCT Entities:
OBJECTIVE: To assess validity of pain and patient global scales in gout. METHODS: The authors used data from pegloticase clinical trials in chronic refractory gout to examine the validity of visual analogue scale (VAS) pain, Short-Form 36 (SF-36) bodily pain subscale and VAS patient global assessment (all scales 0-100). Convergent/divergent validity with clinical characteristics was tested by using Spearman's correlation coefficient. For discriminant ability, the authors compared the change at 6 months between placebo and pegloticase arms and calculated effect size (ES) and standardised response mean (SRM). RESULTS: 212 patients (mean age, 55.4 years, 82% men; 73% with tophaceous gout) provided data. VAS pain was statistically significantly correlated with tender joints (r=0.42), swollen joints (r=0.30), SF-36 physical (r=-0.56) and Mental Component Summary (r=-0.36) and Health Assessment Questionnaire scores (r=0.54; all p-values <0.0001), but not disease duration (r=-0.01; p=0.84), gout flares (r=0.12; p=0.08), comorbidities (r=0.05; p=0.47) or plasma urate (r=0.01; p=0.89). Similar and significant correlation coefficients with tender and swollen joints were noted for VAS patient global assessment (r=0.35 and 0.23; p<0.0012 for both) and SF-36 pain subscale (r=-0.27 and -0.19; p<0.006 for both). Pegloticase group had significantly more improvement than placebo at 6 months, mean (SD): VAS pain, -9.2 (29.3) versus 1.9 (26.4), p=0.0002; SF-36 pain, 14.6 (25.6) versus -0.04 (21.1), p<0.0001; and patient global, -9.3 (26.5) versus 3.4 (22.8), p<0.0001. ES and SRMs in pegloticase group were as follows: VAS pain, 0.34 and 0.30; SF-36 pain, 0.69 and 0.57; patient global, 0.49 and 0.44. CONCLUSION:VAS pain, SF-36 pain and patient global VAS are valid outcome measures in patients with chronic gout.
Authors: Andrew R Moore; Christopher Eccleston; Sheena Derry; Phillip Wiffen; Rae F Bell; Sebastian Straube; Henry McQuay Journal: Pain Date: 2010-06-02 Impact factor: 6.961
Authors: Rebecca Grainger; William J Taylor; Nicola Dalbeth; Fernando Perez-Ruiz; Jasvinder A Singh; Royce W Waltrip; Naomi Schlesinger; Robert Evans; N Lawrence Edwards; Francisca Sivera; Cesar Diaz-Torne; Patricia A MacDonald; Fiona M McQueen; H Ralph Schumacher Journal: J Rheumatol Date: 2009-10 Impact factor: 4.666
Authors: Robert H Dworkin; Dennis C Turk; Michael P McDermott; Sarah Peirce-Sandner; Laurie B Burke; Penney Cowan; John T Farrar; Sharon Hertz; Srinivasa N Raja; Bob A Rappaport; Christine Rauschkolb; Cristina Sampaio Journal: Pain Date: 2009-12 Impact factor: 6.961
Authors: F Salaffi; G Leardini; B Canesi; A Mannoni; A Fioravanti; R Caporali; G Lapadula; L Punzi Journal: Osteoarthritis Cartilage Date: 2003-08 Impact factor: 6.576
Authors: Jasvinder A Singh; William J Taylor; Nicola Dalbeth; Lee S Simon; John Sundy; Rebecca Grainger; Rieke Alten; Lyn March; Vibeke Strand; George Wells; Dinesh Khanna; Fiona McQueen; Naomi Schlesinger; Annelies Boonen; Maarten Boers; Kenneth G Saag; H Ralph Schumacher; N Lawrence Edwards Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666